Decreased Expression of Stomatin Predicts Poor Prognosis in HER2-Positive Breast Cancer

Stomatin expression was an independent prognostic indicator from trastuzumab treatment, with a higher hazard ratio than that of adjuvant trastuzumab.

 BMC Cancer

By continuing to browse this site you permit us and our partners to place identification cookies on your browser and agree to our use of cookies to identify you for marketing. Read our Privacy Policy to learn more.